产品销售收入 - 公司第二季度IBSRELA产品销售收入为3540万美元，同比增长约25%[5] - 公司第二季度XPHOZAH产品销售收入为3710万美元，较第一季度大幅增长[6] - 2024年第二季度IBSRELA产品销售收入为354.45百万美元，XPHOZAH产品销售收入为371.46百万美元[31] - 2024年上半年IBSRELA产品销售收入为638.06百万美元，XPHOZAH产品销售收入为522.97百万美元[31] 财务状况 - 公司第二季度总收入为7320万美元，主要反映产品销售收入增加[10] - 公司第二季度研发费用为1280万美元，销售及管理费用为6470万美元[11][12] - 公司第二季度净亏损为1650万美元，每股亏损0.07美元[13] - 公司现金及投资总额为1.86亿美元[9] - 2024年上半年总收入为1,192.45百万美元，总成本和费用为1,577.53百万美元，其中销售成本为165.64百万美元，研发费用为233.41百万美元，销售及管理费用为1,176.48百万美元[31] - 2024年上半年净亏损为429.72百万美元，每股亏损为0.18美元[31] - 截至2023年12月31日，公司总资产为3,434.88百万美元，其中现金及现金等价物为1,469.90百万美元，长期债务为1,002.49百万美元[29][30] - 2024年第二季度研发费用为127.62百万美元，销售及管理费用为646.54百万美元[31] - 2024年第二季度净亏损为164.54百万美元，每股亏损为0.07美元[31] 未来展望 - 公司2024年全年IBSRELA预计销售收入为1.4亿至1.5亿美元[5] - IBSRELA和XPHOZAH在相关学术会议上展示了更多支持性数据[8] 产品风险 - IBSRELA和XPHOZAH存在严重腹泻等不良反应的警示[15][16][17][22][23]

IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported fin ...

WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of plain language summaries of results from two clinical trials on XPHOZAH® (tenapanor), NORMALIZE and OPTIMIZE, in Current Medical Research and Opinion. The plain language summaries were developed by the authors to help adult pat ...

WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of plain language summaries of results from two clinical trials on XPHOZAH® (tenapanor), NORMALIZE and OPTIMIZE, in Current Medical Research and Opinion. The plain language summaries were developed by the authors to help adult pati ...

Biotech stocks are known for their high volatility and potential for massive gains. The success in the sector often hinges on progressive and often groundbreaking medical advancements. Any concerns relating to upcoming drugs can have severely negative effects on stock prices.As per Precedence Research, the global biotechnology market is projected to grow from $1.38 trillion in 2023 to approximately $4.25 trillion by 2033. The expected growth is largely to be driven by advancements in various biotechnologica ...

文章核心观点 - 预计Ardelyx公司在2024年6月季度报告中将同比下降收益,但收入将同比增长149.6% [1][2][4] - 分析师近期对Ardelyx公司的盈利预期有所上调,这导致了Earnings ESP为正值,预示着公司有可能超出共识预期 [5][12] - 过去四个季度,Ardelyx公司已经连续三次超出了共识EPS预期 [14] 根据相关目录分别进行总结 盈利预期 - 预计Ardelyx公司将在2024年第二季度报告中录得每股亏损0.10美元,同比下降25% [4] - 分析师近期对Ardelyx公司的盈利预期有所上调,Earnings ESP为正值,预示着公司有可能超出共识预期 [5][12] - 过去四个季度,Ardelyx公司已经连续三次超出了共识EPS预期 [14] 收入预期 - 预计Ardelyx公司2024年第二季度收入将达到55.73百万美元,同比增长149.6% [4] 行业比较 - 同行业公司Sage Therapeutics预计2024年第二季度每股亏损1.66美元,同比下降38.1%,收入同比增长243.3% [18] - Sage Therapeutics的Earnings ESP为负值,加上Zacks评级为4星,预示其很难超出共识预期 [19][20]

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, August 1, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2024. To participate in the conference call, please dial (844) 481-2838 (do ...

Lawsuit challenges CMS’s statutory overreach in its determination to include oral-only phosphate-lowering therapies in the End-Stage Renal Disease Prospective Payment System Inclusion of oral-only phosphate lowering therapies within the ESRD PPS limits patient choice and timely access to important innovations and treatment options for unmet needs WALTHAM, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commerc ...

Alexyz3d/iStock via Getty ImagesShares of Ardelyx (NASDAQ:ARDX) took a hit last week after the company said it will not apply to include Xphozah in the Centers for Medicare & Medicaid Services (‘CMS’) End-Stage Renal Disease (‘ESRD’) Prospective Payment System (‘PPS’) Transitional Drug Add-On Payment Adjustment (‘TDAPA’), in an effort to preserve patient access to the drug. This effectively means CMS will not cover Xphozah in 2025, and the drug’s future is highly uncertain. After last week’s decision no ...

MONSEY, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx”) has violated the federal securities laws after the company announced that it had decided not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment (TDAPA). Upon this news, Ardelyx shares have so far fallen nearly 30% in tradin ...